Download PDF
Thromb Haemost 2003; 90(06): 1210-1213
DOI: 10.1055/s-0037-1613425
Case Report
Schattauer GmbH

Phenprocoumon-induced hepatitis as an immunologically mediated drug allergic complication of antithrombotic therapy

Alexandra Dorn-Beineke
,
Abdul-Wahab Hassan
,
Joachim Bräutigam
,
Ralf Hildenbrand
,
Carl-Erik Dempfle
,
Matthias Schwab
Financial support: This work was kindly supported by the Lesser-Loewe-Foundation, Mannheim and the Robert Bosch Foundation, Stuttgart, and the BMBF grant 01GG9846.
Further Information

Publication History

Received 30 May 2003

Accepted after revision 31 July 2003

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E. et al. Molecular cloning, expression, and chromosomal localisation of the human earliest lymphocyte activation antigen AIM/ CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993; 178: 537-47.
    CrossrefPubMedGoogle Scholar
  • 2 Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells 1994; 12: 456-65.
    CrossrefPubMedGoogle Scholar
  • 3 Haustein KN. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon. Semin Thromb Hemost 1999; 25: 5-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Hirtz J, Le Roux Y, Jaouen A. et al. Clinical pharmacology studies with acenocoumarol. Int J Clin Pharmacol Biopharm 1979; 17: 361-5.
    PubMedGoogle Scholar
  • 5 Loebstein R, Yonath H, Peleg D. et al. Interindividual variability in sensitivity to warfarin – nature or nurture?. Clin Pharmacol Ther 2001; 70: 159-64.
    CrossrefPubMedGoogle Scholar
  • 6 He M, Korzekwa KR, Jones JP. et al. Structural forms of phenprocoumon and war-farin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372: 16-28.
    CrossrefPubMedGoogle Scholar
  • 7 Rettie AE, Koop DR, Haining RL. CYP2C. In: Metabolic drug interactions. Levy, Thummel, Trager, Hansten, Eichelbaum, ed Philadelphia Lippincott Williams &: Wilkins; 2000: 75-86.
    Google Scholar
  • 8 Cox D, O’Kennedy R, Thornes RD. The rarity of liver toxicity in patients treated with coumarin (1, 2-benzopyrone). Human Toxicol 1989; 8: 501-6.
    CrossrefPubMedGoogle Scholar
  • 9 Casley-Smith JR, Casley-Smith JR. Frequency of coumarin hepatotoxicity. Med J Aust 1995; 162: 391.
    PubMedGoogle Scholar
  • 10 Ciorciaro C, Hartmann K, Stoller R. et al. Leberschäden durch Coumarin-Antikoagulantien: Erfahrungen der IKS und der SANZ. Schweiz Med Wochenschr 1996; 126: 2109-13.
    PubMedGoogle Scholar
  • 11 De Man RA. Phenprocoumon-induced liver failure. Neth J Med 1993; 43: 91
    PubMedGoogle Scholar
  • 12 Höhler T, Schnütgen M, Helmreich-Becker I. et al. Drug-induced hepatitis: a rare complication of oral anticoagulants. J Hepatol 1994; 21: 447-9.
    CrossrefPubMedGoogle Scholar
  • 13 Ehrenforth S, Scharrer I, Herrmann G. Phenprocoumon-induzierte nekrotisierende Hepatitis. Dtsch Med Wschr 1995; 120: 1529-30.
    PubMedGoogle Scholar
  • 14 Ehrenforth S, Schenk JF, Scharrer I. Liver damage induced by coumarin anticoagulants. Semin Throm Hemost 1999; 25: 79-83.
    PubMedGoogle Scholar
  • 15 Mix H, Wagner S, Böker K. et al. Subacute liver failure induced by phenprocoumon treatment. Digestion 1999; 60: 579-82.
    CrossrefPubMedGoogle Scholar
  • 16 Capoferri M, Realini S, Balestra B. Akute nekrotisierende Hepatitis: eine ungewöhnliche Nebenwirkung oraler Antikoagulation. Praxis 2000; 89: 929-32.
    PubMedGoogle Scholar
  • 17 Hinrichsen H, Lüttges J, Klöppel G. et al. Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. Scand J Gastroenterol 2001; 7: 78017
    PubMedGoogle Scholar
  • 18 Schneider ARJ, Hartmann D, Arnold JC. et al. Phenprocoumon-assoziierte nekrotisierende Hepatitis. Dtsch Med Wschr 2001; 126: 457-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Mardinary M, Brown MR, Fleisher TA. Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen or antigen-induced proliferative capacity in normals. Cytometry 1996; 26: 305-10.
    CrossrefPubMedGoogle Scholar
  • 20 Caruso A, Licenziati S, Corulli M. et al. Flow cytometric analysis of activation markers on stimulated T-cells and their correlation with cell proliferation. Cytometry 1997; 27: 71-6.
    CrossrefPubMedGoogle Scholar